Contribution: Industrial Research Assistance Program – Contributions to Firms
University Health Network
$1,000,000.00
Protecting Frontline Health Care Workers (HCWs) from COVID-19 with lambda interferon Pre-exposure Prophylaxis: An Adaptive Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada (HEROs Trial)
FY 2020-21 · 2020-04-02
Summary
Randomized study that will test the efficacy of lambda interferon to protect front line health care workers from contracting SARS-CoV-2 corona virus which causes COVID-19 disease.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
Other
Business Number
119259505
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2020-04-02 | 2020-21 | $1,000,000.00 |
| 1 | 2020-04-02 | 2020-21 | $1,000,000.00 |
| 2 | 2020-04-02 | 2020-21 | $1,000,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 61 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 61 jours.
Agreement End Date
2021-06-30
Agreement Number
947684
Agreement Start Date
2020-04-02
Agreement Title
Protecting Frontline Health Care Workers (HCWs) from COVID-19 with lambda interferon Pre-exposure Prophylaxis: An Adaptive Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada (HEROs Trial)
Agreement Title (French)
Protéger les travailleurs de la santé de première ligne contre la COVID-19 grâce à la prophylaxie pré-exposition à l'interféron lambda : un essai adaptatif aléatoire et contrôlé par placebo sur plusieurs sites à Toronto, au Canada (essai HEROs)
Agreement Type
Contribution
Agreement Value
$1,000,000.00
Amendment Date
2021-03-03
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Randomized study that will test the efficacy of lambda interferon to protect front line health care workers from contracting SARS-CoV-2 corona virus which causes COVID-19 disease.
Description (French)
Étude aléatoire qui testera l'efficacité de l'interféron lambda pour protéger les travailleurs de la santé de première ligne contre la contamination par le virus corona SRAS-CoV-2 qui cause la maladie COVID-19.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
University--Rosedale
Federal Riding (French)
University--Rosedale
Federal Riding Number
35110
NAICS Code
6221
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
119259505
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
University Health Network
Recipient Operating Name
UHN
Recipient Postal Code
M5G 2C4
Recipient Province or Territory
ON
Recipient Type
N
Reference Number
172-2020-2021-Q1-947684
